These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 27423613)

  • 41. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency.
    Zamboni P; Galeotti R; Menegatti E; Malagoni AM; Gianesini S; Bartolomei I; Mascoli F; Salvi F
    J Vasc Surg; 2009 Dec; 50(6):1348-58.e1-3. PubMed ID: 19958985
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course.
    Silversides JA; Heggarty SV; McDonnell GV; Hawkins SA; Graham CA
    Mult Scler; 2004 Apr; 10(2):149-52. PubMed ID: 15124759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Prognostics factors of renal failure in multiple sclerosis].
    Viart L; Elalouf V; Petit J; Al Khedr A; Kristkowiak P; Saint F
    Prog Urol; 2012 Dec; 22(16):1026-32. PubMed ID: 23178100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.
    Fassas A; Passweg JR; Anagnostopoulos A; Kazis A; Kozak T; Havrdova E; Carreras E; Graus F; Kashyap A; Openshaw H; Schipperus M; Deconinck E; Mancardi G; Marmont A; Hansz J; Rabusin M; Zuazu Nagore FJ; Besalduch J; Dentamaro T; Fouillard L; Hertenstein B; La Nasa G; Musso M; Papineschi F; Rowe JM; Saccardi R; Steck A; Kappos L; Gratwohl A; Tyndall A; Samijn J;
    J Neurol; 2002 Aug; 249(8):1088-97. PubMed ID: 12195460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study.
    Lalmohamed A; Bazelier MT; Van Staa TP; Uitdehaag BM; Leufkens HG; De Boer A; De Vries F
    Eur J Neurol; 2012 Jul; 19(7):1007-14. PubMed ID: 22353360
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Discontinuation and long-term adherence to beta interferon therapy in patients with multiple sclerosis].
    Vicente Iturbe C; Ara Callizo JR; Huarte Lacunza R; Navarro Aznárez H; Serrano Mislata N; Rabanaque Hernández MJ
    Farm Hosp; 2012; 36(2):77-83. PubMed ID: 21820930
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumour necrosis factor alpha gene (TNF-alpha) -376 polymorphism in Hungarian patients with primary progressive multiple sclerosis.
    Losonczi E; Bencsik K; Nagy ZF; Honti V; Szalczer E; Rajda C; Illés Z; Mátyás K; Rózsa C; Csépány T; Füvesi J; Vécsei L
    J Neuroimmunol; 2009 Mar; 208(1-2):115-8. PubMed ID: 19201038
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis.
    Katz Sand I; Krieger S; Farrell C; Miller AE
    Mult Scler; 2014 Oct; 20(12):1654-7. PubMed ID: 24493475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
    Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
    Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progression rates and sample size estimates for PPMS based on the CLIMB study population.
    Raghavan K; Healy BC; Carruthers RL; Chitnis T
    Mult Scler; 2015 Feb; 21(2):180-8. PubMed ID: 25070676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
    Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identical lesion morphology in primary progressive and relapsing-remitting MS--an ultrahigh field MRI study.
    Kuchling J; Ramien C; Bozin I; Dörr J; Harms L; Rosche B; Niendorf T; Paul F; Sinnecker T; Wuerfel J
    Mult Scler; 2014 Dec; 20(14):1866-71. PubMed ID: 24781284
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
    Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
    Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases.
    Brettschneider J; Jaskowski TD; Tumani H; Abdul S; Husebye D; Seraj H; Hill HR; Fire E; Spector L; Yarden J; Dotan N; Rose JW
    J Neuroimmunol; 2009 Dec; 217(1-2):95-101. PubMed ID: 19879655
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Voxel-based assessment of differences in damage and distribution of white matter lesions between patients with primary progressive and relapsing-remitting multiple sclerosis.
    Di Perri C; Battaglini M; Stromillo ML; Bartolozzi ML; Guidi L; Federico A; De Stefano N
    Arch Neurol; 2008 Feb; 65(2):236-43. PubMed ID: 18268194
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.
    Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD
    Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The natural history of multiple sclerosis: a geographically based study: 8: familial multiple sclerosis.
    Ebers GC; Koopman WJ; Hader W; Sadovnick AD; Kremenchutzky M; Mandalfino P; Wingerchuk DM; Baskerville J; Rice GP
    Brain; 2000 Mar; 123 Pt 3():641-9. PubMed ID: 10686184
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study.
    Wilson S; Calocer F; Rollot F; Fauvernier M; Remontet L; Tron L; Vukusic S; Le Page E; Debouverie M; Ciron J; Ruet A; De Sèze J; Zephir H; Moreau T; Lebrun-Frénay C; Laplaud DA; Clavelou P; Labauge P; Berger E; Pelletier J; Heinzlef O; Thouvenot E; Camdessanché JP; Leray E; Dejardin O; Defer G
    Lancet Reg Health Eur; 2023 Jan; 24():100542. PubMed ID: 36426377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An excessive risk of suicide may no longer be a reality for multiple sclerosis patients.
    Kalson-Ray S; Edan G; Leray E;
    Mult Scler; 2017 May; 23(6):864-871. PubMed ID: 28299961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.